Hepatotoxicity From Immune Checkpoint Inhibitors: A Systematic Review and Management Recommendation
Thoetchai (Bee) Peeraphatdit, Jennifer Wang, Matthew A. Odenwald, Shaomin Hu, John Hart, Michael R. Charlton – 13 March 2020 – Immune checkpoint inhibitors (ICIs) are monoclonal antibodies targeting immune checkpoint molecules. ICIs are an immunotherapy for the treatment of many advanced malignancies. The advent of ICIs has been a major breakthrough in the field of oncology, a fact recognized by the 2018 Nobel Prize in Physiology or Medicine being awarded for the discovery.